Delivery Order SPE2DB22D2206-SPE2DB25FJN02
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors valued at $9,253.56 on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price, non-competitive delivery order represents pharmaceutical procurement for military healthcare needs and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $14,002.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 8, 2025. This non-set-aside award was issued on August 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical supply vendor that serves military...
- The Defense Logistics Agency awarded a $32,259.65 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injector pens, with an ultimate completion date of July 29, 2025. This non-set-aside contract represents a competitive award to support federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,211.70 for ENBREL 50 mg/ml SureClick auto-injector pens on July 29, 2025, with an ultimate completion date of July 30, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) designated SPE2DX with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $10,226.52 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injector pens. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 21, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and pharmaceutical distribution...
- The Defense Logistics Agency awarded a delivery order valued at $10,537.97 to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors on July 30, 2025, with a completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $34,601.94 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of ENBREL 50 mg/mL SureClick auto-injector pharmaceutical product. The delivery order, which carries an ultimate completion date of August 25, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $12,541.06 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with a completion date of July 31, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical will be supplied from the contractor's facility in...
- The Defense Logistics Agency awarded a $39,049.72 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price contract serves as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $10,388.67 to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injector pens. This competitive, firm fixed-price delivery order was issued on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Enbrel is a biologic immunosuppressant medication used to treat rheumatoid arthritis and other autoimmune...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJN02Delivery Order
The Defense Logistics Agency awarded a $23,960.38 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injector pens, with an ultimate completion date of August 21, 2025. This non-competitive, firm fixed-price delivery order was issued on August 20, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, supplies critical medical commodities to federal customers including the Defense Health Agency and U.S. Coast Guard through its extensive portfolio of brand-name and generic medications, vaccines, and specialized medical devices. ENBREL (etanercept) is a biologic immunosuppressant commonly used to treat rheumatoid arthritis and other inflammatory conditions, and this procurement supports the Department of Defense's pharmaceutical supply chain requirements for military personnel and beneficiaries. The delivery order exemplifies the company's role as a key vendor in the federal medical supply system, providing rapid fulfillment of specialty pharmaceutical products through the DLA's established prime vendor contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.0k | 8/20/25 |